 |
 |
|
|
|
 |
|
|
|
 |
 |
|
|
01/27/2005
|
|
BOSTON, Jan. 27 /PRNewswire-FirstCall/ -- ViaCell, Inc. announced the completion of its initial public offering of 7,500,000 shares of common stock. In addition, the underwriters of its initial public offering exercised their over-allotment option in full and purchased an additional 1,125,000 shares of common stock. All such shares were sold by ViaCell at the initial public offering price of $7 per share, less underwriting discounts and commissions.
Credit Suisse First Boston and UBS Investment Bank acted as joint book- running managers, and Lazard and Leerink Swann & Company acted as co-managers for this offering.
Copies of the final prospectus relating to this offering may be obtained from Credit Suisse First Boston LLC, Prospectus Department, One Madison Avenue, Level 1B, New York, NY 10010 (telephone number: 212-325- 2580); or UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171 (telephone number: 212-821-3000).
ViaCell, Inc. is a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company is developing a pipeline of proprietary product candidates intended to address cancer, cardiac diseases and infertility. ViaCell's portfolio of proprietary technologies includes Selective Amplification technology and USSC. The Company's lead cord-blood derived stem cell therapy product candidate, CB001, is currently in a Phase I clinical trial. ViaCell offers expecting families the option of preserving their baby's cord blood stem cells through its Viacord business.
A registration statement relating to the common stock has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ViaCell, Inc.
CONTACT: Stephen G. Dance of ViaCell, Inc., +1-617-914-3400,sdance@viacellinc.com; or Media Contact-US: Justin Jackson of Burns McClellan,+1-212-213-0006, jjackson@burnsmc.com
Web site: http://www.viacord.com/
|
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
